The COVID-19 Long Haul Foundation

Treatment, Referral & Educational Support for COVID-19 Illnesses & Vaccine Injury

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants

Lorenza Bellusci, Hana Golding, and Surender Khurana Journal of Clinical Investigation Published 2023 – More infoView PDF  Convalescent plasma (CP) and hyperimmune intravenous immunoglobulins (IVIGs) are routinely used to treat patients with COVID-19. […]

C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

Bruna M. Silva,1,2 Giovanni F. Gomes,1 Flavio P. Veras,1 Seppe Cambier,3 Gabriel V.L. Silva,1,2 Andreza U. Quadros,1 Diego B. Caetité,1,2 Daniele C. Nascimento,1,2 Camilla M. Silva,1,2 Juliana C. Silva,1 Samara Damasceno,1 Ayda H. Schneider,1 Fabio Beretta,3 Sabrina S. Batah,4 Icaro M.S. Castro,5 Isadora M. Paiva,1 Tamara […]

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial

Susanna Naggie, MD, MHS1,2; David R. Boulware, MD, MPH3; Christopher J. Lindsell, PhD4; et alThomas G. Stewart, PhD5; Alex J. Slandzicki, MD6; Stephen, C. Lim,  MD Jonathan Cohen, MD8;  David Kavtaradze, MD9,  Arch Amon, MD10, et. al for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. JAMA. 2023;329(11):888-897. doi:10.1001/jama.2023.1650 Question  Does ivermectin, […]